Zymark and Bayer Collaborate on Cell-Based Transcription Assay | GenomeWeb

NEW YORK, Jan 2 – Bayer and Zymark of Hopkinton, Mass. have developed a cell-based assay kit that allows laboratories to design assays for any gene target or type of cell and run an automated assay, the companies announced Tuesday.

The package includes Bayer’s QuantiGene assays, HV kit, and ProbeDesigner software, as well as Zymark’s Staccato workstation.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.

Clinicians look to fold non-medical data into algorithms to predict patients' health, the Wall Street Journal reports.

Connecticut's biotech investment is leading to the building of labs to house new startups, the Associated Press reports.

Craig Venter's Health Nucleus aims to change preventive medicine, according to the Robb Report.